相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Matthias Pinter et al.
GUT (2021)
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Matthias Pinter et al.
JAMA ONCOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
Mitsunori Morita et al.
BMC CANCER (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
Jakob M. Riedl et al.
CANCERS (2020)
C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
Tsuguru Hayashi et al.
PLOS ONE (2020)
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
Stephan Spahn et al.
CANCERS (2020)
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentrereal- world cohort
Bernhard Scheiner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation
Tobias Meischl et al.
PLOS ONE (2019)
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Peter R. Galle et al.
LIVER INTERNATIONAL (2019)
The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma
Chandan Sanghera et al.
LIVER INTERNATIONAL (2019)
C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions
Rachel V. Jimenez et al.
FRONTIERS IN IMMUNOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
Sanna Iivanainen et al.
ESMO OPEN (2019)
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma
Vincenzo Mazzaferro et al.
GASTROENTEROLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
Hitomi Takada et al.
PLOS ONE (2018)
Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers
Takaki Akamine et al.
SURGICAL ONCOLOGY-OXFORD (2018)
Review article: systemic treatment of hepatocellular carcinoma
Matthias Pinter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Cancer and liver cirrhosis: implications on prognosis and management
Matthias Pinter et al.
ESMO OPEN (2016)
Usefulness of a new inflammation-based scoring system for prognostication of patients with hepatocellular carcinoma after hepatectomy
Shozo Mori et al.
AMERICAN JOURNAL OF SURGERY (2015)
Towards better clinical prediction models: seven steps for development and an ABCD for validation
Ewout W. Steyerberg et al.
EUROPEAN HEART JOURNAL (2014)
How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma
Florian Hucke et al.
JOURNAL OF HEPATOLOGY (2014)
Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells
Angela D. Pardee et al.
JOURNAL OF IMMUNOLOGY (2014)
Cancer-related inflammation and treatment effectiveness
Connie I. Diakos et al.
LANCET ONCOLOGY (2014)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma
Wolfgang Sieghart et al.
HEPATOLOGY (2013)
Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria
Christophe Duvoux et al.
GASTROENTEROLOGY (2012)
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI)
David J. Pinato et al.
JOURNAL OF HEPATOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C-Related Hepatocellular Carcinoma
Gia L. Tyson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status
Yun-feng Shan et al.
MEDICAL ONCOLOGY (2011)
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
Hajime Uno et al.
STATISTICS IN MEDICINE (2011)
Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression
Eek Joong Park et al.
CELL (2010)
Assessing the Performance of Prediction Models A Framework for Traditional and Novel Measures
Ewout W. Steyerberg et al.
EPIDEMIOLOGY (2010)
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
Stephen Kaptoge et al.
LANCET (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Ikappa B Kinaseβ/Nuclear Factor-κB Activation Controls the Development of Liver Metastasis by Way of Interleukin-6 Expression
Shin Maeda et al.
HEPATOLOGY (2009)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Human C-reactive protein binds activating Fcγ receptors and protects myeloma tumor cells from apoptosis
Jing Yang et al.
CANCER CELL (2007)
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production
Willscott E. Naugler et al.
SCIENCE (2007)
分享论文
